[Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].

Published in: Terapevticheskii arkhiv (2023)

The study demonstrated the positive effect of the drug UDCA (Ursofalk) on reducing the degree of liver steatosis, on carbohydrate, lipid metabolism, body weight in patients with DM in combination with NAFLD.

Keyphrases

body weight
insulin resistance
fatty acid
metabolic syndrome
skeletal muscle
drug induced